Dexmedetomidine vs Placebo for Pediatric Cleft Palate Repair
Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of administering intravenous
dexmedetomidine as a single preemptive dose to placebo in reducing the total 24 hour dose of
opioids as measured on a weight adjusted morphine equivalent basis.